

Herpes virus infection drives HIV infection among non-injecting drug users in New York

28 June 2014

HIV and its transmission has long been associated excellent job of reducing HIV among persons who with injecting drug use, where hypodermic syringes inject drugs and we must now put more efforts into are used to administer illicit drugs. Now, a newly reported study by researchers affiliated with New York University's Center for Drug Use and HIV Research (CDUHR) in the journal PLOS ONE, shows that HIV infection among heterosexual noninjecting drug users (no hypodermic syringe is used; drugs are taken orally or nasally) in New York City (NYC) has now surpassed HIV infection among persons who inject drugs.

The study, "HSV-2 Co-Infection as a Driver of HIV Transmission among Heterosexual Non-Injecting Drug Users in New York City," was conducted among drug users entering the Mount Sinai Beth Israel drug treatment programs in NYC. The researchers found that HIV infection among noninjecting drug users doubled over the last two decades, from 7% infected in the late 1990s (n= 785) to 14% (n=1764) currently. During this same time-frame, HIV infection among persons who inject drugs fell to 10%.

The increased efficiency for transmitting HIV occurs even when persons with herpes simplex virus 2 (HSV-2) are between outbreaks, as herpes increases both susceptibility to and transmissibility of HIV. More than half of the non-injecting drug users in the study were infected with HSV-2.

"Heterosexual intercourse is usually not very efficient for transmitting HIV, but the efficiency of heterosexual transmission nearly triples in the presence of herpes simplex virus type 2," notes the study's lead author, Don Des Jarlais, PhD, Deputy Director, Research Methods and Infectious Diseases Cores, Center for Drug Use and HIV Research (CDUHR) and Professor of Psychiatry and of Preventive Medicine at Mount Sinai Beth Israel. "In New York City, we have done an

reducing sexual transmission associated with noninjecting drug use."

The study concludes that an increase in HIV infection among these non-injecting drug users is better considered as an increase in HSV- 2/HIV coinfection rather than simply an increase in HIV prevalence. Additional interventions (such as treatment as prevention and pre-exposure prophylaxis) are needed to reduce further HIV transmission from HSV-2/HIV co-infected noninjecting drug users.

The City Department of Health and Mental Hygiene has initiated a program "treatment as prevention," in which HIV infected persons are given anti-viral medications to both protect their own health and to reduce the chances that they will transmit HIV to others. There are also new federal recommendations to provide anti-retroviral medications to HIV uninfected persons at high risk for becoming infected.

"If we can implement these programs on a large scale, we should be able to control sexual transmission of HIV in the city, and achieve the goal of an "End to the AIDS Epidemic," said Dr. Des Jarlais.

Provided by New York University



APA citation: Herpes virus infection drives HIV infection among non-injecting drug users in New York (2014, June 28) retrieved 11 October 2022 from https://medicalxpress.com/news/2014-06-herpes-virus-infection-hiv-non-injecting.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.